Evernorth data shows fewer prescriptions have been filled for certain anti-viral medications than in previous years, but an uptick in January shows that respiratory illnesses are circulating in the U.S.

During the panel, experts discussed ways they have navigated patient recruitment challenges.

With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.

Plan sponsors should be aware of the effects the law will have on Medicare Part D over the coming years.

The complex nature of copay assistance programs requires operational agility on the part of specialty pharmacies.

Evernorth Health Services has introduced Evernorth Oncology Benefit Services, which will be available to eligible commercial plan sponsors in 2025, with plans to expand over time.

Researchers have identified sleep apnea as a common comorbidity among patients with cardiodiabesity.

The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.